FR054

FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect. FR054 induces in different breast cancer cells a dramatic decrease in cell proliferation and survival. In particular, in a model of Triple Negative Breast Cancer (TNBC) cells, MDA-MB-231, these effects are correlated to FR054-dependent reduction of both N- and O-glycosylation level that cause also a strong reduction of cancer cell adhesion and migration. . Note: The correct structure for FR054 is CAS#35954-65-5 which is the 6S-isomer. Some vendors are selling wrong structure for FAR054 (the incorrect structure has CAS#10378-06-0, which is the 6R-isomer). Note this product is being supplied as ethanol solution at 100mg/mL.

Product information

CAS Number: 35954-65-5

Molecular Weight: 329.30

Formula: C14H19NO8

Chemical Name: 5H-Pyrano[3, 2-d]oxazole-6, 7-diol, 5-[(acetyloxy)methyl]-3a, 6, 7, 7a-tetrahydro-2-methyl-, diacetate (ester), (3aR, 5R, 6S, 7R, 7aR)-

Smiles: CC1=N[C@@H]2[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O[C@@H]2O1

InChiKey: WZFQZRLQMXZMJA-KSTCHIGDSA-N

InChi: InChI=1S/C14H19NO8/c1-6-15-11-13(22-9(4)18)12(21-8(3)17)10(5-19-7(2)16)23-14(11)20-6/h10-14H,5H2,1-4H3/t10-,11-,12-,13-,14+/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: To be determined

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Ricciardiello F, Bergamaschi L, De Vitto H, Gang Y, Zhang T, Palorini R, Chiaradonna F. Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor. Cells. 2021 Feb 18;10(2):431. doi: 10.3390/cells10020431. PMID: 33670598; PMCID: PMC7923121.
2. Ricciardiello F, Gang Y, Palorini R, Li Q, Giampà M, Zhao F, You L, La Ferla B, De Vitto H, Guan W, Gu J, Zhang T, Zhao Y, Chiaradonna F. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Oncogene. 2020 May;39(20):4103-4117. doi: 10.1038/s41388-020-1260-1. Epub 2020 Mar 31. PMID: 32235891.
3. Ricciardiello F, Votta G, Palorini R, Raccagni I, Brunelli L, Paiotta A, Tinelli F, D'Orazio G, Valtorta S, De Gioia L, Pastorelli R, Moresco RM, La Ferla B, Chiaradonna F. Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis. Cell Death Dis. 2018 Mar 7;9(3):377. doi: 10.1038/s41419-018-0405-4. PMID: 29515119; PMCID: PMC5841296.

Products are for research use only. Not for human use.